ACADIA Pharmaceuticals Inc (ACAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) has a cash flow conversion efficiency ratio of -0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.73 Million) by net assets ($1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ACADIA Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of ACADIA Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
ACADIA Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACADIA Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avicopter PLC
SHG:600038
|
-0.092x |
|
Assured Guaranty Ltd
F:DHU
|
0.010x |
|
XJ Electric Co Ltd
SHE:000400
|
0.061x |
|
Huaneng Power International Inc
F:HUP1
|
0.033x |
|
Perimeter Solutions SA
NYSE:PRM
|
0.014x |
|
Stride Inc
NYSE:LRN
|
0.068x |
|
InnoDisk
TWO:5289
|
-0.116x |
|
Kontoor Brands Inc
NYSE:KTB
|
0.121x |
Annual Cash Flow Conversion Efficiency for ACADIA Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ACADIA Pharmaceuticals Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see ACADIA Pharmaceuticals Inc (ACAD) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.23 Billion | $109.84 Million | 0.089x | -58.42% |
| 2024-12-31 | $732.79 Million | $157.72 Million | 0.215x | +456.38% |
| 2023-12-31 | $431.75 Million | $16.70 Million | 0.039x | +113.58% |
| 2022-12-31 | $400.41 Million | $-114.03 Million | -0.285x | -22.59% |
| 2021-12-31 | $540.89 Million | $-125.66 Million | -0.232x | -6.98% |
| 2020-12-31 | $627.01 Million | $-136.17 Million | -0.217x | -0.46% |
| 2019-12-31 | $699.13 Million | $-151.13 Million | -0.216x | +38.16% |
| 2018-12-31 | $479.08 Million | $-167.47 Million | -0.350x | +46.20% |
| 2017-12-31 | $335.29 Million | $-217.86 Million | -0.650x | -60.09% |
| 2016-12-31 | $518.41 Million | $-210.41 Million | -0.406x | +33.43% |
| 2015-12-31 | $199.76 Million | $-121.80 Million | -0.610x | -184.03% |
| 2014-12-31 | $309.49 Million | $-66.43 Million | -0.215x | -23.06% |
| 2013-12-31 | $182.13 Million | $-31.77 Million | -0.174x | +31.48% |
| 2012-12-31 | $84.98 Million | $-21.63 Million | -0.255x | +70.11% |
| 2011-12-31 | $23.36 Million | $-19.90 Million | -0.852x | -136.24% |
| 2010-12-31 | $29.69 Million | $-10.70 Million | -0.361x | +68.18% |
| 2009-12-31 | $12.11 Million | $-13.73 Million | -1.133x | +7.43% |
| 2008-12-31 | $52.99 Million | $-64.87 Million | -1.224x | -153.92% |
| 2007-12-31 | $113.93 Million | $-54.93 Million | -0.482x | +21.83% |
| 2006-12-31 | $67.16 Million | $-41.42 Million | -0.617x | -19.83% |
| 2005-12-31 | $39.37 Million | $-20.26 Million | -0.515x | +23.70% |
| 2004-12-31 | $30.68 Million | $-20.69 Million | -0.674x | -461.90% |
| 2003-12-31 | $-52.67 Million | $-9.82 Million | 0.186x | -19.17% |
| 2002-12-31 | $-40.09 Million | $-9.24 Million | 0.231x | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more